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Abstract: A series of titanium oxides 
was prepared by a surfactant template 
method (STM) and used as carrier to 
sustain the release of ibuprofen, chosen 
as model drug. The STM procedure 
provides an efficient method to prepare 
TiO2 matrices with both high surface 
area (if compared with those obtained 
with the traditional synthetic approach) 
and a well defined mesoporous texture. 
Some parameters of the synthetic 
procedure were varied: pH, surfactant 
and thermal treatment. The physico-
chemical nature of the surface carriers 
were investigated by means of N2 
physisorption measurements and FT-IR 
analyses. The effect of the drug amount 
on the release kinetic was also 
investigated. The drug delivery was 
evaluated in vitro in four different 
physiological solutions (simulating the 
gastro-intestinal tract) in order to 
analyze the behaviour of the TiO2-
based systems if formulated as oral 
DDS. The optimized approach turns out 
to be a good alternative to the classical 
methods employed to prepare efficient 
TiO2-based drug delivery systems.  
Keywords: Titanium oxide • Surface 
texture • Porosity • Drug delivery • In 
vitro test 
 
 
Introduction 
 
One of the main goals in material design is the optimization of a 
preparation method that can be easily modulated as a function of the 
final application. This is a key point in the development of materials 
devoted to be used as reservoirs in the drug delivery process, in 
particular when a strict control of the release rate of the drug is 
required. In this field it is fundamental to identify the correlations 
between the features of the carriers and the control on the drug 
release. In general, a substrate must have the ability to incorporate 
the required amount of drug, preserve it and delivery it gradually as 
the time goes by and eventually address it to a specific target site. 
High surface area, large pore volume and proper pore size are 
fundamental prerequisites for a matrix to be able to ensure loading 
of the support with the desired amount of the molecule guest, thus 
increasing its adsorption capacity [1-3]. Moreover, by varying surface 
area, dimensions and distribution of the pore size and surface 
properties (hydrophilic-hydrophobic groups, acid-basic functions, 
etc), both drug loading and drug release can be opportunely 
modulated [2-5]. In the light of these considerations, it is clear that a 
wise choice of the material and of the procedure adopted for its 
synthesis is necessary. The investigations reported in literature deal 
with either polymeric materials [6] and/or inorganic oxides, such as 
nanoporous alumina, porous silica, nanostructured ceramics [7-9] and 
many synthetic approaches are available, among which: template 
method  [10 ,11] and sol-gel  [12 ,13].  
In particular, the use of ordered mesoporous silica as carrier 
(MCM-41, MCM-48, SBA-15) provides an effective way for the 
realisation of controlled delivery systems: the key factors for the 
modulation of the release are both pores dimension and ordered 
structure [14-16]. At the same time, the sol-gel synthesis is very 
attractive, as its major advantage is that the matrix can be 
simultaneously generated in the presence of the drug molecule in a 
one-step process. Moreover, the physico-chemical features of silica 
can be suitably modulated by both control and opportune variation 
of the process parameters (such as composition of precursor mixture, 
catalysts, pH, aging). In particular, by a one-pot sol-gel process it is 
possible to obtain hybrid inorganic-organic matrices [9]: in fact, the 
introduction of the proper functional groups allows a high control of 
the drug delivery process. Increasing attention has been recently 
devoted to titanium-based drug delivery systems (DDS) [17]. 
Titanium is well known for its biomedical applications since the 
1970s in the field of orthopaedic implants. In fact, titanium, titanium 
based alloys and TiO2 systems are among the most common implant 
materials (such as cardiovascular stents, joint replacements and 
dental implants) used in the human body because of their desirable 
mechanical strength, low density, excellent resistance to corrosion 
and lack of cytotoxic effects [18,19]. The addition of controlled drug 
delivery properties to the well known features of titanium-based 
materials could expand its potential applications in the biomedical 
field, and this represents a very attractive research outcome.  
Many studies can be found in literature about the preparation of 
nanostructured titanium-based DDS. The research is focused, in 
particular, on either the use of titania nanotubes or on sol-gel 
derived matrices to sustain the release of antibiotic, anti-
inflammatory or anti-tumoral drugs [20-23]. In a recent work [24] we 
have investigated the ability of a series of commercial TiO2 matrices 
to control the release of ibuprofen. We have observed a close 
correlation between the pores dimension of the matrix and the 
release rate of the embedded drug: it is then possible to design a 
drug delivery device as a function of the final application (i.e. 
dimension of the drug, therapeutic action duration, etc). In order to 
achieve this goal, in the present work we have studied a series of 
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TiO2 matrices prepared by using a surfactants-template method. The 
possibility of using a supramolecular aggregate of surfactants for the 
preparation of ordered mesoporous titania samples is a topical 
subject and many efforts have been made to develop an effective 
synthetic way [25,26]. Unfortunately, these approaches, that are 
successful for the preparation of mesoporous silica usually, fail for 
TiO2: in fact, it is quite difficult to obtain thermally stable 
mesoporous titania carriers.  
So, in this work we have pursued a double goal: the 
development of a reliable procedure for the synthesis of mesoporous 
titania materials and its application in the design of titania-based 
drug delivery systems. In particular we focused our attention on the 
feasibility of this system as oral DDS. Despite of the growing 
interest in using these materials as biomedical devices, there are a 
few studies concerning lab-made titania used for the controlled 
release of drugs, in particular if formulated for an oral 
administration. 
For this purpose we have carried out a preliminary study on the 
release behaviour in a simulated gastro-intestinal environment. We 
think that these experimental results could be useful to the scientific 
community in consideration of the few data available on this topic. 
With the aim to control the textural features of the carriers and, 
in particular, pores size dimension and organization and surface area, 
we have investigated the effect of some parameters (surfactant type, 
pH, calcination temperature, drug amount) on the final properties of 
the materials, in order to single out the optimal synthetic conditions 
and the best drug delivery performance.  
 
Results and Discussion 
 
Effect of the template agent 
 
In a recent work [24] we have demonstrated the close correlation 
between the porous structure and the surface properties of a series of 
nanoporous commercial titania carriers and their performance as 
DDS. In the light of these results, the first aim of this work has been 
the synthesis of titania carriers with well controlled physico- 
chemical (surface and textural) features by a reliable synthetic 
method. The use of a supramolecular aggregate of surfactants as 
directing agents allows a strict control of the textural features of the 
final oxide by the opportune choice of the operative parameters. The 
application of this method to the synthesis of nanoporous titania 
carriers is actually of great interest, but the process variables and 
their influence have not been clearly explained yet. In order to detect  
the optimal synthetic parameters we have compared, at first, the 
delivery behaviour of two TiO2 carriers prepared by using either a 
cationic (CTA-Br) or a polymeric neutral (P-123) surfactant, 
respectively. For the preparation of the matrix, using CTA-Br, we 
have partly followed the procedure optimized for the synthesis of 
the MCM-41 [27] by the opportune modification of some synthetic 
parameters. On the other hand, in the case of P-123, we have 
adapted the synthesis, recently reported in literature [28]. The use of a 
cationic or a neutral surfactant implies the choice of different 
operative conditions, among which: molar ratio of the reagents, 
aging time, pH. In particular, the use of CTA-Br requires an alkaline 
environment (pH~11), whereas with P-123 we have operated in 
drastic acidic conditions. The pH plays a key role in directing the 
final features of the TiO2 carriers. In fact, as reported by Bradley et 
al. [29], the hydrolysis rate of Ti(OBu)4 is lower in basic environment 
than in either acidic or neutral conditions and the condensation 
kinetics are systematically enhanced under basic conditions. The 
base-catalyzed condensation should be directed toward the middle 
rather than the end of chains, leading to more compact, highly 
branched species. The drug was introduced on the matrices by 
incipient wetness impregnation, an effective and reliable method for 
the preparation of porous oxide/drug composites, as previously 
reported [15]. 
In a typical experiment, the corresponding drug delivery profiles 
are reported in Figure 1. The two delivery profiles are quite different. 
For the TPi6 systems, at the end of the delivery experiment, only a 
limited fraction (~ 30%) of the initially embedded drug is released 
from the tablet; the delivery profile shows an increasing and gradual 
trend only in the first 3 h. On the other hand, in the case of the TCi6 
sample, the release is rather controlled and almost all the drug is 
released at the end of the delivery test. 
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Figure 1. Drug delivery profile for TCi6 and TPi6 systems 
In order to explain these results, FTIR analyses were resorted to in 
order to shed some light on the physico-chemical features of the 
various TiO2 materials. 
All systems have been characterized by means of FTIR 
spectroscopy in order to obtain information about: (i) all surface 
terminations (i.e., intrinsic and/or added functionalities); (ii) the 
possible nature of the interaction between the TiO2 surface and the 
embedded ibuprofen drug. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. FTIR spectra relative to the various TiO2 materials before and after IBU 
addition. All spectra have been recorded after a plain activation in vacuo at IR beam T. 
 
FTIR spectra are very similar for all the investigated systems. As for 
the spectra relative to the plain TiO2 systems (T-600), all of them 
exhibit the typical OH pattern of titania, i.e.: 
(i)  a complex band located in the 3600-3700 cm-1 range 
which can be ascribed, on the basis of its spectral behaviour and of 
literature data [23], to the stretching mode () of Ti-OH species 
free from hydrogen bonding interactions; 
(ii)  a broad envelope, located in the 3600-3000 cm-1 range, 
which can be ascribed to the  of all H-bonded OH groups 
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present at the surface of the solid [24]. This is not surprising, as an 
activation in vacuo at RT can only get rid of the physisorbed 
fraction of (associated/undissociated) water molecules present at the 
surface of the various TiO2 systems. 
As for the envelope located at  < 1800 cm-1, it is mainly made up 
of a component centred at  1630 cm-1, ascribable to the HOH 
mode of undissociated water molecules. At lower , the different 
components can be ascribed to the spectral modes of surface 
carbonate/hydrogen-carbonate species generated by the reaction of 
CO2 with the surface species of an ionic oxide like TiO2 
[25]. 
When Ibuprofen (IBU) is added to the TiO2 matrix, it is possible to 
observe that in all cases the above described typical OH pattern of 
titania is strongly affected by the presence of the bioactive molecule: 
see curves TCi6 and TPi6 in Figure 2. In fact, the envelope of bands 
ascribable to the “free” Ti-OH species ( in the 3620-3700 cm-1 
range) is totally absent in the case of all the titania+IBU samples, as 
confirmed by the differential spectrum (see curve TCi6 – TC6 in 
Figure 2). Moreover, it is worth noting that the presence of 
additional bands on the profile of the titania/drug composite is due 
to the presence of IBU. In fact, in the high region (2750-3100 cm-
1), new sharp bands appear: their spectral behaviour allows to assign 
them to the C-H stretching modes (~2800-3100 cm) of all CH-
containing species of either aliphatic or aromatic nature [30] present 
in the ibuprofen molecule. At low frequency (<1800 cm), intense 
and broad bands are also present: these represent either the spectral 
bending C-H counterparts of the above-described stretching modes 
of either all CH-containing species or the CO (~1695 cm-1) of the 
carboxylic residue present in the drug. 
All these features confirm the presence of the bioactive 
molecule on the matrices and its interaction with the titania surface 
is likely to take place by hydrogen bond (bands relative to OH 
species upon drug loading disappear whereas bands relative to CH 
and/or CO species appear after IBU loading). 
HR-TEM analyses of the TiO2 powders before and after IBU 
addition have been carried out: the corresponding images are 
reported in Figure 3, respectively referred to the plain TC6 (left-
hand section) and to the TCi6 (right-hand section) materials. 
 
 
 
 
 
 
 
Figure 3. HR-TEM images. TC6 (left-hand section) and to the TCi6 (right-hand section). 
The plain TiO2 material exhibits particles of 20-30 nm average size, 
characterized by very smooth edges: these particles exhibit also a 
highly crystalline nature, as witnessed by the very high incidence of 
either fringe patterns, due to low indexes crystal planes, or Moirè’s 
fringe patterns. The detailed inspection of the fringes distances 
indicates that the most frequently exposed planes belong to the (101) 
anatase polymorph [ICCD card File No. 21-1272]. When IBU is 
present, the general morphological features seem to be a little 
different: TiO2 particles are still both highly crystalline and belong 
to the same phase, but their edges are either more disordered or 
present amorphous nature, most likely due to the effect of IBU 
addition. 
These results are significant but they cannot justify the very 
different delivery profiles. In order to shed some light on these 
differences physisorption analyses were carried out and the obtained 
results are reported in Table 1 and the corresponding curves are 
shown in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 
Adsorption
/desorption 
isotherms 
(a) and 
pore 
diameter 
distribution 
(b) for 
TCi6 and 
TPi6 
samples. 
 
 
Table 1. 
Physisorpti
on data for 
the 
samples 
wit and 
without 
ibuprofen. 
 
 
 
 
 
 
 
 
 
 
 
Sample 
Ibuprofen 
amount 
(mg) 
BET 
surface 
area 
(m2/g) 
Total 
Pore 
Volume  
(mL/g) 
Pore 
diameter 
(nm) 
TC4  130 0.3 3-8 
TCi4 200 57 0.2 3-10 
TC5  108 0.3 3-30 
TCi5 200 67 0.2 3-30 
TC6  49 0.2 6-20 
TCi6 
 
 
200 34 0.2 5-20 
 
TP6  160 0.4 2-5 
TPi6 200 64 0.2 3-8 
TCi5/ibu100 100 70 0.2 3-30 
 
TCi5/ibu400 400 64 0.2 3-30 
 
 
TCi5 (after 
release, pH1.2) 
200 65 0.2 3-30 
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Upon nitrogen adsorption, both materials exhibit a  type IV isotherm 
typical of a mesoporous system but some differences concerning the 
isotherm shape are evident. The CTA-Br derived sample presents a 
clear type-H1 hysteresis loop that is typical of materials with 
cylindrical mesopores characterized by a uniform distribution of the 
dimensions. The pores size distribution, calculated on the adsorption 
branch by the BJH method, is unimodal and centred at 15 nm. The 
hysteresis loop of the TPi6 sample is shifted towards lower partial 
pressures, indicating the presence of smaller pores as confirmed by 
the BJH curve, that shows a unimodal pore size distribution with 
dimension between 4 and 10 nm. The comparison between the drug 
delivery profiles and the pores size distribution suggests a close 
correlation between pores dimension and drug diffusion process. 
The relative smaller pores of the Pluronic-derived sample can 
explain, in fact, its partial release: most of the drug remains trapped 
into its relatively small pores (d < 8 nm). 
On the basis of these results, the work was continued by focusing 
the investigation only on the matrices prepared with CTA-Br. We 
have investigated, in particular, the effect of two parameters: the 
calcination temperature and the drug amount.  
 
Effect of the thermal treatment 
 
It is well known that the thermal treatment directly influences the 
textural properties of a material: in order to investigate the effect of 
this variable the as-synthesized matrix has been calcined at 450 °C 
(TC4) and 550 °C (TC5)  and compared with the carrier treated at  
the highest temperature (TC6). In order to evaluate if the thermal 
treatment can affect the surface features of the these samples, also in 
this case FTIR analyses were carried out; unfortunately, no relevant 
differences have been detected among them and the TCi6 materials 
and consequently no spectra have been here reported for the sake of 
brevity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Adsorption/desorption isotherms (a) and pore diameter distribution (b) for 
TCi4, TCi5 and TCi6 samples. 
 
On the contrary, physisorption analysis revealed significant 
differences: the corresponding adsorption-desorption isotherms and 
the pore size distribution curves for the ibuprofen-loaded matrices 
are shown in Figure 5, whereas the relevant data are reported in 
Table 1. 
All the samples exhibit a type IV isotherm. The hysteresis loop of 
the TCi4 sample is broad and located in a p/p0 range between 0.5 
and 0.9; the corresponding BJH pore size distribution, in the 
adsorption branch, indicates the presence of relatively small pores 
with a mean dimension in the 3-8 nm interval. The TiO2 carriers 
treated at higher temperatures show a very similar isotherm shifted 
toward highest p/p0 values suggesting the presence of larger pores. 
In fact, the pores size distribution curves are respectively centred at 
10 nm for the TCi6 material and at 15 nm for the TCi5 carrier. The 
distribution of the sample calcined at 550 °C is rather wide, as it is 
comprised in the 3-30 nm range. The BET surface area of the drug 
loaded and pressed carriers are relatively low (between 45 and 70 
m2/g); on the contrary the surface area values of the corresponding 
supports are about 100 m2/g, higher than that obtained by the 
traditional synthetic method  (i.e., precipitation) [31] or by other 
template assisted sol-gel preparations [26,32]. This evidence indicates 
the efficiency of the adopted synthetic procedure. 
The effects of the different textural properties on the drug delivery 
behaviour is shown in Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Drug delivery profile for TCi4, TCi5, TCi6 matrices. 
 
The drug delivery is almost complete for both the carriers treated at 
high temperatures, whereas only 70% of the ibuprofen loaded is 
released from the TCi4 matrix at the end of the release test. The 
latter carrier reaches the maximum drug delivered amount after 24 h, 
whereas in the case of both the other matrices the delivery process 
continues gradually and well controlled up to 48 h. A careful 
analysis of the delivery  profiles of TCi5 and TCi6 samples in the 
first two hours of analysis indicates another interesting difference: it 
is evident that the slope of the release curve of the TCi5 carrier is 
much more marked. This behaviour could be more suitable for an 
efficient DDS, in fact it ensures the rapid achievement of the 
minimal therapeutic concentration which is essential for the correct 
management of the drug. Once again, this behaviour can be ascribed 
to the pores organization of the samples: in particular, the presence 
in the carriers calcined at the highest temperature of a significant 
fraction of pores of relatively high dimension (~ 10 nm) ensures the 
complete release of the drug amount adsorbed with a profile very 
similar to that expected for an ideal DDS. Moreover, an optimal 
pores size distribution, allowing a fair control of the delivery 
process, is likely to exist in the case the TCi5 carrier: in particular, it 
ensures an expected fast release in the first 2 h of analysis and a 
good control of the delivery rate up to 48 h. 
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In order to evaluate the effect of the drug amount on the delivery 
behaviour, a last test has been carried considering only the TC5 
carrier. Considering the drug concentrations in the different 
commercial formulations, we have investigated a concentration 
range between 100 and 400 mg. The delivery profiles are reported in 
Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Effect of drug amount on the drug delivery behaviour. 
 
The matrix containing the lowest concentration of drug (100 mg 
ibuprofen) exhibits a partial release, accounting for 50% of the total. 
The desorption profile shows a gradual release only within the first 
interval of analysis, as it already stabilizes after 6 hours, indicating 
that the drug is no longer released. This is in contrast with what 
obtained for the sample with the highest drug content (400 mg 
ibuprofen), for which the desorption is very fast. The corresponding 
curve shows a pronounced slope within the first 100 min and after 
only 6 hours most of the active principle is desorbed (98%). 
The sample containing 200 mg of ibuprofen exhibits the best release 
profile: the drug is released almost completely (the percentage of 
ibuprofen released is  90% of the loaded amount) and the trend is 
gradual and continuous even after 48 hours. 
In the case of the investigated TiO2 carriers, the drug delivery 
process is mainly controlled by diffusion: the drug dissolves in the 
release medium and then diffuses from the matrix into the solution 
along the solvent-filled porous channels. This process is governed 
by both physical (steric effect) and chemical interactions between  
drug and carrier. We have demonstrated that for matrices with 
different textural properties the key factor in directing the drug 
delivery is played by the pore organization (pore size and pores size 
distribution). The matrices loaded with different drug amount 
possess the same pores size dimension and specific surface area (see 
Table 1) and, in this case, the drug delivery process is evidently 
controlled not only from physical factors, but also from chemical 
interactions with the matrix surface. 
In an attempt to justify and explain the experimental results we 
reported in graphical form (see Fig. 8) the way by which the active 
molecule may be distributed in the matrix and then released. 
As shown in Figure 8, in the case of the sample in which 400 mg of 
drug were loaded, the ibuprofen molecules are, plausibly,  
distributed inside the pores and on the surface of the material. The 
drug on the surface is the first to be released with no real control of 
the rate of desorption; on the contrary, for the drug contained within 
the porous structure, the rate of desorption is controlled by both 
shape and size of the pores of the support, thus resulting more 
gradual. In the case of the sample with the lowest concentration of 
active molecule (100 mg ibuprofen) only a small fraction of this is 
found at the surface, as the majority remains within the channels of 
the support interacting with it through weak chemical interaction 
(i.e., H-bonding, see FTIR data section). 
 
 
 
 
 
Figure 8. Ibuprofen distribution in the TiO2 porous channels as function of drug amount. 
 
In this case the "steric" effect (due to the porous structure) adds even 
more direct chemical effect because of the interaction of ibuprofen 
molecules with the hydroxyl groups of the matrix. In other words, in 
the case of the matrix containing only 100 mg of ibuprofen each 
molecule is affected by a greater number of interactions with the 
surface than in the case of the matrix loaded with a higher content; 
consequently, ibuprofen is more strongly bonded to the titania 
surface and the diffusion process is hindered. All these factors could 
explain the partial release exhibited by this system. 
In the case of the sample at intermediate concentration (200 mg), an 
almost optimal situation has been reached. The percentage of drug 
present on the surface allows to achieve in a short time the minimum 
effective therapeutic concentration, while the percentage of drug in 
the porous channels is responsible for a gradual release.  
Probably by modifying the matrix through the introduction of proper 
functional groups at the surface and/or through the modulation of its 
textural properties, it could be possible to obtain a controlled release 
regardless of the total amount of drug loaded. 
 
Delivery behaviour along the gastro-intestinal tract 
 
The last part of the work was devoted to the study of the in vitro 
behavior of the TiO2-based drug delivery systems in the gastro-
intestinal tract, in order to simulate the conditions that the formulate 
would experience when designed for oral administration. To this end, 
For this purpose, the release by from the best sample (TCi5, 200 mg 
of ibuprofen) has been studied in solutions reproducing the 
physiological environment of the stomach and small intestine. 
The first solution simulates the gastric fluid (pH 1.2); in this 
medium, drug release has not been observed. In order to explain this 
experimental evidence we have first evaluated, the effect of the 
strong acid environment on the TiO2 matrix. For this purpose 
nitrogen physisorption has been resorted to. Fig. 9  reports the 
adsorption-desorption isotherms of the matrix before and after the 
release test in gastric solution (24 h). 
It may can be noted that the isotherm remains substantially unaltered, 
indicating that the texture of the material has been preserved (also 
surface area and pore diameter remain unchanged; see Table 1). The 
carrier suffered no stress associated with the environment and it is 
plausible to think that it kept inside all the drug initially loaded (in 
the case of drug desorption a partial texture modification is 
 6 
expected). In order to check this last hypothesis, the tablet used for 
the test was consistently washed with a buffered solution at pH 7.4. 
In the solution, 200 mg of ibuprofen have been detected by means of 
HPLC analysis: it corresponds the amount initially loaded into the 
matrix. Another factor to consider is that ibuprofen in acidic 
aqueous solutions has a very low solubility [36]. This may have 
inhibited the desorption of the active agent from the matrix. In any 
case, the tests carried out have demonstrate that the TiO2 matrix is 
stable in gastric solution and is able to preserve the integrity of the 
active principle.  
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Figure 9. Adsorption/desorption isotherms for TCi5 sample: as prepared  and after the 
release test in the gastric solution. 
 
Thereafter we analyzed the behavior of the DDS in the intestinal 
fluid; it is at the level of small intestine that the active molecule is 
adsorbed, and it is here that the drug should perform its therapeutic 
action. In order to realistically simulate the intestinal environment, a 
pH 6.8 buffered solution containing pancreatin was prepared. The 
pancreatin is constituted by a mixture of enzymes (amylase, lipase, 
and protease) produced by exocrine glands present in the intestinal 
mucosa of mammals. In Fig. 10 reports the desorption profiles for 
the TCi5 sample studied in two pH 6.8 buffered solutions with and 
without pancreatin, respectively. The observed behaviors are very 
different. In the solution prepared without the addition of enzymes, 
the desorption profile recovers to that observed at pH 7.4; on the 
contrary, the presence of pancreatin, significantly changes the 
release kinetics. The drug diffusion rate from the matrix to the 
solution has considerably slowed down, indicating a much more 
gradual release. The amount of drug delivered after 48 hours is 
slightly lower than that desorbed at pH 6.8 in the absence of 
pancreatin, but the release profile is growing and longer times would 
allow the release of almost all the loaded ibuprofen. 
The obtained results are useful because, to the best of our 
knowledge, they represent the first example of a study of a TiO2-
based DDS in a gastro-intestinal environment. 
Moreover, we can state that not only TiO2-based DDS act very well 
in a medium that simulates the intestinal environment but it seems to 
have improved to some extent its performance (more gradual and 
controlled release).  
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Figure 10. Drug delivery profiles for TCi5 in intestinal solution with and without 
pancreatin. 
 
 
 
Conclusion 
 
The study demonstrated the actual potential of the titanium dioxide 
as a carrier for the development of drug delivery systems. In 
particular we have optimized a synthetic approach that allows an 
effective modulation of both the morphological and structural 
properties (porous organization) of the matrix and the drug release. 
Moreover we have observed that the features of the carrier should be 
properly designed taking into account the final amount of drug and 
the administration form. The study has provided a series of useful 
information to the development of a TiO2-based drug delivery 
device that can be specifically formulated for a particular 
therapeutic application. In particular we have demonstrated the 
feasibility of the TiO2 carrier for the formulation of an oral DDS. 
Experimental Section 
TiO2 powders by CTA-Br 
These matrices were prepared by using the CTA-Br as structure directing agent. A 
given amount of cetyltrimethylammonium bromide (CTABr, ALDRICH) was added to 
a NaOH aqueous solution. The mixture was stirred slowly at room temperature for 40 
min. The resulting solution was combined with a suspension of Ti(OBu)4 (ALDRICH) 
in Bu(OH)4 as source of titania and the reaction mixture was stirred at room temperature 
for 3 h. The molar composition of the resultant gel was: 1: TiO2, 0.12: CTABr, 0.53: 
NaOH, 590: H2O. The gel was crystallized in static condition at 75 °C for 40 h. The 
solid product was filtered, washed with deionized water, dried at room temperature and 
then calcined at three different temperatures (450 °C, 550 °C and 600 °C). The final 
material was labelled: TCx (T=titanium; C=CTA-Br; x=calcination temperature). 
TiO2 powders by P-123 
In this synthesis we have used non-ionic surfactants. In a typical preparation,  the 
surfactant P-123, EO20PO70EO20, (3.6 g) (Aldrich) was dissolved in a solution of water 
(5.4 mL), ethanol (47 mL) and HCl (4 mL) with stirring. Then, the titania precursor, 
Ti(OBu)4, (21 mL) was slowly added to the homogeneous solution with stirring at room 
temperature. The obtained gel was transferred in a crystallizer and dried at 35 °C for 24 
h. The solid product was recovered and crushed. The resulting powder was then 
calcined at 600 °C in order to remove the template. The obtained sample was labelled: 
TPx (T=titanium; P=P-123; x=calcination temperature) 
Synthesis of TiO2/ibu samples 
The drug was embedded on the carriers by incipient wetness impregnation as previously 
reported in ref. [15]. In a typical synthesis, a proper amount of ibuprofen sodium salt (in 
order to obtain a concentration of 100, 200 and 400 mg of ibuprofen/g of TiO2) was 
dissolved in ethanol and added to 1g of the titania support containing a pore volume 
equal to that of the added solution. Capillary action draws the solution into the pores. 
The drug/TiO2 composite was then dried at 35 °C for 12 hours to get off the volatile 
components within the solution. The obtained samples were conformed (pressure 2.5 
Ton/cm2 for 5 minutes) as capsules (diameter 1.2 cm; thickness: 0.5 cm). The final 
samples were labelled TCix and TPix (i=ibuprofen). 
Delivery release (in vitro study) 
In vitro study of ibuprofen release from the supports was performed as follows. 
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In a typical experiment, a capsule was soaked in a proper volume (10 mL) of a 
physiological solution and maintained at 37 °C. Samples of 1 mL were removed from 
the solution at predetermined times and replaced by the same volume of fresh medium. 
The drug concentration in the liquid phase was evaluated by UV spectrometry at 272 
nm (Perkin-Elmer λ40 instrument).  
The release was studied in four physiological solutions: 
1. Commercial pH 7.4 buffered saline solution (TRIS BUFFERED SALINE 
SOLUTION, FLUKA) 
2. Acid buffered solution (pH 1.2).  This solution was prepared by dissolving 
2.0 g of NaCl (Fluka) in 7.0 mL of HCl and making up to volume (1 L) 
with ultra-pure water. (U.S. PHARMACOPEIA) 
3. Buffered solution (pH 6.8). This solution was prepared by dissolving 6.8 g 
of potassium phosphate monobasic (FLUKA) in 250 mL of water into a 
flask of 1 L. 77 mL of a solution 0.2 N NaOH (FLUKA) and 500 mL of 
ultra pure water were added. Then a solution 0.2 N NaOH was added until 
the desired pH (6.8). (U.S. PHARMACOPEIA) 
4. Intestinal Simulated Fluid (pH 6.8). This solution was prepared by adding 
10.0 g of pancreatine (ALDRICH) to the pH 6.8 buffered solution. (U.S. 
PHARMACOPEIA) 
Calibration curve of ibuprofen was determined by taking absorbance vs ibuprofen 
concentration between 0 and 2000 ppm as reference parameters. The effective drug 
concentration in solution was calculated on the basis of the following equation [33 ]: 
 
 
where Ceff is the corrected concentration at time t, Capp is the apparent concentration at 
time t, v is the volume of sample taken and V is the total volume of the dissolution 
medium. 
In order to check the reliability of the collected data, a test was carried out in the 
conditions previously reported by taking a single sample from the dissolution medium 
at the end of the release experiment. We have obtained the same drug concentration 
value of that calculated on the basis of the formula for a drug release test studied with 
multiple sampling. 
In order to check for reproducibility, each release test has been carried out in duplicate 
by collecting, each time, the data analysis simultaneously from two identical tablets. 
Characterization 
Specific surface area and pores size distribution were obtained from N2 adsorption-
desorption isotherms at 77 K (MICROMERITICS ASAP 2000 Analyser). Surface area 
was calculated by the BET equation [34], whereas the mesopores size distribution was 
determined by the BJH method [35], applied to the N2 adsorption isotherm branch. Prior 
to the adsorption experiments all the analysed samples were outgassed in vacuum at 
room temperature (RT) for 12 h. 
FTIR spectra were obtained on a BRUKER 113v spectrophotometer (2 cm-1 resolution, 
MCT detector). All materials were inspected in the form of self-supporting pellets (10 
mg cm-2). All samples were activated in controlled atmosphere at IR beam temperature 
(BT, namely  60 °C) in quartz cells connected to a gas vacuum line, equipped with 
mechanical and turbo molecular pumps (residual pressure p<10-5 Torr). Samples have 
been treated (i.e., evacuated) only at BT from 1 up to 60 min in order to get rid of all 
physisorbed species.  
HR-TEM images were collected with a JEOL JEM 3010UHR (300 kV) transmission 
electron microscope fitted with a single crystal LaB6 filament and an Oxford INCA 
Energy TEM 200 energy dispersive X-ray (EDX) detector. All samples were dry 
deposited on Cu “holey” (200 mesh) carbon grids. 
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